<DOC>
	<DOC>NCT02713867</DOC>
	<brief_summary>The primary objective of this study is to show that PFS (progress-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks is non-inferior to nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).</brief_summary>
	<brief_title>A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Histologically or cytologically documented Squamous or nonSquamous Nonsmall cell lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following multimodal therapy Patients must have received prestudy nivolumab for up to 12 months and have 2 consecutive tumor assessments confirming Complete response (CR), Partial response (PR), or Stable disease (SD) Measurable disease before start of prestudy nivolumab treatment Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 02 Carcinomatous meningitis Untreated, symptomatic Central nervous system (CNS) metastases Symptomatic interstitial lung disease Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>